MedTrace Logo

Safety and Efficacy of ATG003 in Patients With AMD Receiving Anti-VEGF

NCT00607750 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2010-10-28

No results posted yet for this study

Summary

This study is a double-masked, randomized, placebo-controlled study of the safety and preliminary efficacy of ATG003 (topical mecamylamine) in patients receiving maintenance injections of either ranibizumab or bevacizumab. Study Hypothesis: Mecamylamine could be effective in the treatment of neovascular AMD.

Conditions

  • Age-Related Macular Degeneration

Interventions

DRUG

ATG003 (mecamylamine)

1% Ophthalmic solution, eyedrop BID, 48 weeks

DRUG

Placebo

Placebo eyedrops, BID, 48 weeks

Sponsors & Collaborators

  • CoMentis

    lead INDUSTRY

Principal Investigators

  • Carl Grove, MS · Comentis, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
56 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-05-31
Primary Completion
2010-04-30
Completion
2010-05-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00607750 on ClinicalTrials.gov